{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Androgen+Receptor+Antagonists",
    "query": {
      "intervention": "Androgen Receptor Antagonists"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 72,
    "total_pages": 8,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Androgen+Receptor+Antagonists&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-13T19:35:30.319Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03068910",
      "title": "Hyperandrogenemia and Altered Day-night LH Pulse Patterns",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Hyperandrogenism",
        "Polycystic Ovary Syndrome",
        "Puberty"
      ],
      "interventions": [
        {
          "name": "Micronized progesterone",
          "type": "DRUG"
        },
        {
          "name": "Spironolactone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "FEMALE",
        "summary": "10 Years to 17 Years · Female only"
      },
      "enrollment_count": 32,
      "start_date": "2016-07-21",
      "completion_date": "2025-12-01",
      "has_results": false,
      "last_update_posted_date": "2025-08-05",
      "last_synced_at": "2026-09-13T19:35:30.319Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03068910"
    },
    {
      "nct_id": "NCT04597099",
      "title": "Androgen Blockade and Progesterone Augmentation of Gonadotropin Secretion",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "PCOS",
        "Polycystic Ovary Syndrome"
      ],
      "interventions": [
        {
          "name": "Micronized progesterone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Flutamide",
          "type": "DRUG"
        },
        {
          "name": "Estradiol patch",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "30 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 30 Years · Female only"
      },
      "enrollment_count": 10,
      "start_date": "2022-10-26",
      "completion_date": "2025-10-01",
      "has_results": false,
      "last_update_posted_date": "2023-11-02",
      "last_synced_at": "2026-09-13T19:35:30.319Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04597099"
    },
    {
      "nct_id": "NCT05891795",
      "title": "Clascoterone for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Clascoterone 1% Top Cream",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2024-07-22",
      "completion_date": "2026-06",
      "has_results": false,
      "last_update_posted_date": "2026-04-30",
      "last_synced_at": "2026-09-13T19:35:30.319Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05891795"
    },
    {
      "nct_id": "NCT07202247",
      "title": "Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Carcinoma",
        "Recurrent Prostate Carcinoma"
      ],
      "interventions": [
        {
          "name": "Antiandrogen Therapy",
          "type": "DRUG"
        },
        {
          "name": "Behavioral Intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Cardiac Computerized Tomographic Angiography",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Electronic Health Record Review",
          "type": "OTHER"
        },
        {
          "name": "Internet-Based Intervention",
          "type": "OTHER"
        },
        {
          "name": "Lifestyle Counseling",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Medical Device Usage and Evaluation",
          "type": "OTHER"
        },
        {
          "name": "Nutritional Intervention",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Referral",
          "type": "OTHER"
        },
        {
          "name": "Semaglutide",
          "type": "DRUG"
        },
        {
          "name": "Short-Term Fasting",
          "type": "OTHER"
        },
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL",
        "PROCEDURE",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "79 Years",
        "sex": "MALE",
        "summary": "30 Years to 79 Years · Male only"
      },
      "enrollment_count": 60,
      "start_date": "2025-11-05",
      "completion_date": "2028-04-09",
      "has_results": false,
      "last_update_posted_date": "2026-08-17",
      "last_synced_at": "2026-09-13T19:35:30.319Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07202247"
    },
    {
      "nct_id": "NCT07016399",
      "title": "Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anatomic Stage II Breast Cancer AJCC v8",
        "Anatomic Stage IIIA Breast Cancer AJCC v8",
        "Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Breast Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Darolutamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Epirubicin",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Surgical Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Ultrasound Imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Vandana Abramson",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2025-09-09",
      "completion_date": "2033-10",
      "has_results": false,
      "last_update_posted_date": "2025-10-30",
      "last_synced_at": "2026-09-13T19:35:30.319Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07016399"
    },
    {
      "nct_id": "NCT03896984",
      "title": "Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer (mCRPC)"
      ],
      "interventions": [
        {
          "name": "Radium-223 (Xofigo, BAY88-8223)",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 346,
      "start_date": "2019-03-18",
      "completion_date": "2020-12-14",
      "has_results": false,
      "last_update_posted_date": "2021-12-29",
      "last_synced_at": "2026-09-13T19:35:30.319Z",
      "location_count": 1,
      "location_summary": "Whippany, New Jersey",
      "locations": [
        {
          "city": "Whippany",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03896984"
    },
    {
      "nct_id": "NCT02849990",
      "title": "A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage III Prostate Adenocarcinoma AJCC v7",
        "Stage III Prostate Cancer AJCC v7",
        "Stage IV Prostate Adenocarcinoma AJCC v7",
        "Stage IV Prostate Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Abiraterone Acetate",
          "type": "DRUG"
        },
        {
          "name": "Apalutamide",
          "type": "DRUG"
        },
        {
          "name": "Degarelix",
          "type": "DRUG"
        },
        {
          "name": "Indomethacin",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 22,
      "start_date": "2017-03-09",
      "completion_date": "2020-12-10",
      "has_results": true,
      "last_update_posted_date": "2022-01-13",
      "last_synced_at": "2026-09-13T19:35:30.319Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02849990"
    },
    {
      "nct_id": "NCT07593079",
      "title": "Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer",
        "Recurrent Prostate Cancer",
        "Metastatic Prostate Cancer",
        "Prostate Cancer Recurrent",
        "Prostate Cancer Metastatic"
      ],
      "interventions": [
        {
          "name": "Bicalutamide",
          "type": "DRUG"
        },
        {
          "name": "Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography",
          "type": "DEVICE"
        },
        {
          "name": "18F-rhPSMA-7.3",
          "type": "DRUG"
        },
        {
          "name": "PROSTest",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 20,
      "start_date": "2026-10-31",
      "completion_date": "2028-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-11",
      "last_synced_at": "2026-09-13T19:35:30.319Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07593079"
    },
    {
      "nct_id": "NCT05917470",
      "title": "A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "ONCT-534",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oncternal Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 21,
      "start_date": "2023-09-20",
      "completion_date": "2024-09-12",
      "has_results": true,
      "last_update_posted_date": "2024-12-11",
      "last_synced_at": "2026-09-13T19:35:30.319Z",
      "location_count": 9,
      "location_summary": "San Francisco, California • Detroit, Michigan • Omaha, Nebraska + 6 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05917470"
    },
    {
      "nct_id": "NCT06190899",
      "title": "Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "mCRPC (Metastatic Castration-resistant Prostate Cancer)",
        "Genital Diseases, Male",
        "Urogenital Diseases, Male",
        "Prostatic Disease",
        "Prostatic Neoplasms, Castration-Resistant",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Gedatolisib",
          "type": "DRUG"
        },
        {
          "name": "Darolutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celcuity Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 54,
      "start_date": "2024-01-01",
      "completion_date": "2030-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-09-13T19:35:30.319Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06190899"
    }
  ]
}